Simoctocog alfa

Drug Profile

Simoctocog alfa

Alternative Names: Factor VIII - Octapharma; Human-cl rhFVIII - Octapharma; Nuwiq; rFactor-VIII-Octapharma ; rFVIII-Octapharma

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Developer Cardinal Health; Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 09 Dec 2017 Pharmacokinetics data from the preclinical studies in Haemophilia A presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 23 Aug 2017 Interim efficacy data from the phase III the NuProtect trial in Haemophilia A released by Octapharma
  • 22 May 2017 Additional pharmacokinetics data from the phase IIIb NuPreviq trial in Haemophilia A released by Octapharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top